Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases.
Bioorg Med Chem Lett. 2010 Jul 15;20(14):4045-9. doi: 10.1016/j.bmcl.2010.05.096. Epub 2010 May 27.
Bioorg Med Chem Lett. 2010.
PMID: 20561787
Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing.
Reader JC, Matthews TP, Klair S, Cheung KM, Scanlon J, Proisy N, Addison G, Ellard J, Piton N, Taylor S, Cherry M, Fisher M, Boxall K, Burns S, Walton MI, Westwood IM, Hayes A, Eve P, Valenti M, de Haven Brandon A, Box G, van Montfort RL, Williams DH, Aherne GW, Raynaud FI, Eccles SA, Garrett MD, Collins I.
Reader JC, et al.
J Med Chem. 2011 Dec 22;54(24):8328-42. doi: 10.1021/jm2007326. Epub 2011 Nov 23.
J Med Chem. 2011.
PMID: 22111927
Free PMC article.
Item in Clipboard
Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors.
Dai J, Yang L, Addison G.
Dai J, et al.
Mini Rev Med Chem. 2019;19(18):1531-1543. doi: 10.2174/1389557519666190617152011.
Mini Rev Med Chem. 2019.
PMID: 31288716
Review.
Item in Clipboard
Cite
Cite